**Core tip:** Magnetic resonance imaging (MRI) is accurate in evaluating Crohn's disease (CD) activity and treatment efficacy, but endoscopy (CD endoscopic index of severity) is still the first choice. There are few available data about the concordance between MRI and endoscopy findings before and after treatment. This study provides evidence that MRI indicators are the most sensitive when the disease progresses.

INTRODUCTION
============

Crohn's disease (CD) is an inflammatory bowel disease that may involve the entire gastrointestinal tract\[[@B1]\]. The morbidity of CD has increased in recent years\[[@B2]\]. CD is characterized by segmental and transmural inflammation with nearly 70% involvement of the small bowel, particularly the terminal ileum\[[@B3],[@B4]\]. Since CD can easily recur, accurate and comprehensive evaluation and follow-up are essential to design an individualized treatment program\[[@B5]\].

Magnetic resonance imaging (MRI) of bowels can not only display eventual lesions in the bowel mucosa and sub-mucosa, but also show mesenteric vessel changes and complications. MRI is an important method in the non-invasive diagnosis of CD\[[@B6]-[@B10]\]. The Crohn's Disease Endoscopic Index of Severity (CDEIS)\[[@B11]\] is calculated based on endoscopy findings and can only show mucosal ulcers and stenosis. It is generally used to assess CD activity and the accuracy of MRI indicators. Nevertheless, there are few available data about the strength of the association between MRI and CDEIS for the evaluation of CD before and after treatment.

It is currently uncertain whether MRI abnormalities are concordant with changes in CDEIS and whether MRI is only a supplementary/accessory assessment method to endoscopy or could be substituted to endoscopy during follow-up. Of course, MRI is a non-invasive examination, improving the patients' quality of life and compliance to follow-up. Tielbeek et al\[[@B12]\] showed that MRI is fairly reproducible but had a moderate agreement with CDEIS; nevertheless, they did not examine the two examinations during follow-up or before/after treatment. Similar results were observed by Rimola et al\[[@B6],[@B13]\], but again without follow-up or treatment efficacy assessment.

Therefore, the aim of the present study was to examine the correlation and concordance between multiple MRI findings and CDEIS changes before and after CD treatment. The results could improve our understanding of CD and provide non-invasive modalities for examining the efficacy of treatments.

MATERIALS AND METHODS
=====================

Study design and patients
-------------------------

This was a retrospective study of 104 patients with CD and treated at the Ruijin Hospital between March 2015 and May 2016. The project was approved by the ethics committee of the Ruijin Hospital. The need for individual consent was waived because of the retrospective nature of the study.

All patients diagnosed with CD during the study period were included. The exclusion criteria were: (1) Poor MR image quality that could not be used for diagnosis and measurements; or (2) incomplete clinical data. The diagnosis of CD was based on the criteria from the World Health Organization (WHO)\[[@B14]\]. These criteria are: (1) Non-contiguous/segmental lesions visible by imaging, endoscopy, and/or the resected specimen; (2) manifesting as paving stones/longitudinal ulcer visible by imaging, endoscopy, and/or the resected specimen; (3) inflammatory lesions of the entire wall based on clinical manifestations and/or resected specimen showing abdominal masses, and stenosis visible by imaging and endoscopy; (4) histopathological manifestations of non-cheese-like granuloma; (5) cleft/fistula visible by imaging, endoscopy, and/or the resected specimen; and (6) anal lesions visible by clinical manifestations and/or biopsy/resected specimen. The diagnosis of CD is made in the presence of: (1) Criteria 1+2+3 and any one of 4, 5, or 6; or (2) criterion 4 and any two of 1, 2, or 3\[[@B14]\].

Endoscopic and MRI examinations were performed within 7 days. The disease course ranged from 1 to 5 years in all patients.

A first MRI and endoscopy were performed in the 104 included patients. According to the CDEIS score\[[@B11]\] before treatment, the patients were classified as active CD (CDEIS \> 6) or inactive CD (CDEIS ≤ 6). A second MRI and endoscopy were conducted in 61 active CD patients after 24-26 wk of medical therapy with glucocorticoids, infliximab (IFX), or adalimumab (ADA).

Endoscopic examination
----------------------

Intestinal preparation was performed routinely the night before endoscopy. Double balloon enteroscopy was performed using an oral intubation depth of about 220 cm and a mean anal intubation depth of 120 cm. Colonoscopy was performed by pushing the endoscope from the anus to the distal ileum. All endoscopic examinations were performed by the same two gastroenterologists.

CDEIS
-----

CDEIS was determined as previously reported\[[@B11]\]: CDEIS = (12 × the number of bowel segments with deep ulcers + 6 × the number of bowel segments with superficial ulcers + affected bowel surfaces with no ulcer + ulcerated surface) ÷ the total number of affected segments + 3 × the number of ulcerated stenosis + 3 × the number of stenosis with no ulcer.

MRI
---

All patients were instructed to fast overnight prior to the MRI examination. The patients were requested to take polyethylene glycol electrolyte powder at 8 PM the day before MRI. Isotonic mannitol solution (2.5%; 2000 mL) was prepared by adding 250 mL of hyperosmotic mannitol solution (0.05 kg of mannitol, concentration of 20%) to 1750 mL of water. Each patient was given three to four 500-mL glasses of isotonic mannitol solution (total, 1500-2000 mL) to optimize the distention of the small bowel. Each glass was given within 10 min. The first glass was given at 40-45 min before MRI. All patients completed bowel preparation before MRI.

All MRI examinations were performed using a 1.5 T MRI unit (GE Signa, HDxt, GE Healthcare, Waukesha, WI, United States). Patients were placed in the supine position with an abdomen coil. MRI was performed with the following sequences: (1) Transverse fast imaging employing steady-state acquisition (FIESTA): Echo time/repetition time (TE/TR) 1.34/3.559 ms, slice thick/gap 5/1 mm, flip angle 55, bandwidth 125, number of excitation (NEX) 1.0, frequency (Freq) 224, field of view (FOV) 40 × 40 cm; (2) coronal T2 Weight Single-Shot Fast Spin Echo (T2WSSFSE): TE/TR 74.56/1800 ms, slice thick/gap 5/1 mm, bandwidth 31.25, Freq 288, FOV 40 cm × 40 cm; (3) coronal FIESTA: TE/TR 1.364/3.285 ms, slice thick/gap 5/1 mm, flip angle 55, bandwidth 125; (4) transverse diffusion weight imaging (DWI): b values were 0, 600 s/mm^2^, TE/TR 67.5/1800 ms, slice thick/gap 5/1 mm, Freq 128, NEX 2.0; and (5) coronal Liver Acquisition with Volume Acceleration (LAVA) dynamic enhanced scan: TE/TR 1.452/3.12 ms, slice thickness/gap 4-4.4/1 mm, flip angle 12, bandwidth 125, Freq 288, FOV 40 cm × 40 cm; contrast agent, Magnevist 0.2 mL/kg, injection rate of 2 mL/s, enhanced scan point of 20, 50, and 90 s after contrast agent injection.

All MR images were independently reviewed by two experienced gastrointestinal radiologists who were blinded to the CDEIS results. Since the CDEIS represents the worst segment seen during endoscopy, the radiologists selected the worst segment on MRI for analysis. In the present study, each lesion observed during MRI could be matched to the endoscopy findings.

T2WI can show the intestinal wall thickening, serosal edema (T2WI high signal), and mucosal defects suggesting ulcers\[[@B6]-[@B11],[@B15]\]. For each individual, bowel thickness was measured using the T2WI sequence. Wall edema\[[@B6]-[@B11],[@B15]\] (hyperintensity on T2WI of bowel wall relative to the signal of the psoas muscle), ulcer in mucosa\[[@B6]\] (deep depression in the mucosal surface of a thickened segment), and reactive lymph nodes (enlarged \> 1 cm) were observed in T2WI. LAVA dynamic enhanced sequence was used to evaluate\[[@B4],[@B16]\]: (1) Wall enhancement pattern: layer stratified enhancement or non-layer stratified enhancement; (2) changes in morphology including shortened mesenteric border, pseudodiverticulum, and stenosis; and (3) perienteric exudation, wall edema, ulcer in mucosa, reactive lymph nodes, perienteric exudation, morphological changes, and layer stratified enhancement, each defined as present or absent.

For patients in the active phase, regions of interest (ROIs) of \< 0.5-cm^2^ were placed on the mucous layer of the lesion segment. In active CD, the mucous layer can be seen clearly due to edema in the sub-mucous layer. For inactive CD, the ROI was placed on the whole bowel wall since the mucous and sub-mucous layers cannot be differentiated. According to a study by Semelka et al\[[@B17]\], quantitative measurement of ROIs of wall signal intensity (WSI) was conducted before and after intravenous contrast administration. Relative contrast enhancement (RCE) was calculated according to: RCE = (WSI~post-enhancement~ - WSI~pre-enhancement~)/(WSI~pre-enhancement~) × 100 × SD~noisepre-enhancement~/SD~noise\ post-enhancement~), where SD~noise\ pre-enhancement~ is the average of three standard deviations (SDs) of the signal intensity measured outside of the body before enhancement, and SD~noise\ post-enhancement~ presents the same noise after enhancement.

DWI can be used to measure the movement of water molecules in living bodies. In the presence of acute inflammation, the edema, exudation of intestinal wall tissue, and elevated inflammatory cytokine levels limit the movement of the water molecules in tissues and cells (*i.e*., the diffusion is limited). Hence, the DWI signals increase while apparent diffusion coefficient (ADC) values decrease. Those values are reversed when inflammation improves\[[@B6]-[@B11],[@B15]\]. In DWI sequences, ROIs of ADC placed on the bowel wall of CD lesions were measured using the Functool Software, and the average values were obtained. A simplified Magnetic Resonance Index of Activity (MaRIA) was calculated for each segment using the formula 1.5 × wall thickness (mm) + 0.02 × RCE + 5 × edema + 10 × ulceration.

Artery enhancement sequence on T1W1 shows the blood supply of the intestine. aRCE is the enhancement rate during arterial phase and represents the degree of blood supply. pRCE is the blood supply during the portal phase. dRCE is the blood supply during the period of delay. In the presence of acute inflammation, the enhancement rates of the various phases are elevated. If the peak value of the enhancement curve is delayed, the inflammation is likely to be improved or chronic\[[@B6]-[@B11],[@B15]\]. The average RCE (total RCE, tRCE; arterial phase RCE, aRCE; portal phase RCE, pRCE; delay phase RCE, dRCE) and ADC values of the lesions in each patient were obtained. ∆tRCE, ∆aRCE, ∆pRCE, ∆dRCE, ∆ADC, ∆MaRIA, ∆thickness, and ∆CDEIS were defined as ∆CDEIS = (indicators after treatment-indicators before treatment)/indicators before treatment.

If the lesions were improved after medical treatment of CD, the following MRI manifestations could be seen: (1) T2WI showed that the thickening of the intestinal wall was alleviated, edema was alleviated or had disappeared, and mucosal ulcers were healed; (2) dynamic T1W1 enhancement sequence showed that the enhancement of the lesion segment had weakened, and the intestinal wall was no longer stratified; (3) the exudation surrounding the intestines was reduced or had disappeared, and the enlarged lymph nodes surrounding the intestines had shrunk; and (4) DWI sequence showed that the signals of the diseased segment were reduced and ADC values were increased.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 19.0 for Windows (IBM, Armonk, NY, United States). Categorical variables (intestinal wall edema, ulcer in mucosa, reactive lymph nodes, perienteric exudation, wall enhancement pattern, and morphological changes) were analyzed using the Spearman correlation. Continuous variables (bowel thickness, tRCE, aRCE, pRCE, dRCE, ADC values, MaRIA) were expressed as mean ± standard deviation, and the Pearson correlation analysis was performed. ∆MRI indicators were analyzed with ∆CDEIS using the Pearson correlation. An inter-observer agreement evaluation between the two radiologists was performed using the kappa statistics. Two-sided *P*-values \< 0.05 were considered statistically significant.

RESULTS
=======

Characteristics of the patients
-------------------------------

Table [1](#T1){ref-type="table"} presents the characteristics of the patients. Among the 104 patients, 61 patients (male/female, 36/25; mean age, 27.5 ± 11.4 years) were classified as having active CD (CDEIS \> 6) and 43 patients (male/female, 24/19; mean age, 24.4 ± 8.0 years) as having inactive CD (CDEIS ≤ 6). Gender, age, disease duration, and disease location were not significantly different between the two groups (all *P* \> 0.05). C-reactive protein (CRP) levels were higher in the active group than in the inactive group (*P* \< 0.001).

###### 

Characteristics of the patients before treatments

                          **All *n* = 104**   **Active *n* = 61**   **Inactive *n* = 43**   ***P* value**
  ----------------------- ------------------- --------------------- ----------------------- ---------------
  Gender (M/F)            59/45               36/25                 23/20                   0.230
  Age                     31.37 ± 9.56        27.5 ± 11.4           34.44 ± 5.37            0.650
  Disease duration        3.5                 3.9                   3.3                     0.550
  Disease location                                                                          
  Rectum                  0                   0                     0                       
  Sigmoid/left colon      4                   2                     2                       
  Transverse colon        14                  7                     7                       
  Right colon             16                  10                    6                       
  Ileum                   70                  42                    28                      
  Treatment regimen                                                                         
  Glucocorticoid          23                  23                    0                       
  IFX                     18                  18                    0                       
  ADA                     20                  20                    0                       
  Edema                   61                  61                    0                       \< 0.001
  Reactive lymph nodes    25                  16                    9                       0.311
  Mucosal ulcer           49                  38                    11                      \< 0.001
  Enhancement pattern     61                  61                    0                       0.006
  Morphological changes   31                  12                    19                      0.023
  Perienteric exudation   38                  38                    0                       \< 0.001
  CRP (mg/L)              18.34 ± 8.45        25.12 ± 4.12          5.14 ± 0.98             \< 0.001
  ADC (mm^2^/s)           1.87 ± 0.471        1.598 ± 0.383         1.949 ± 0.431           0.001
  Thickness (mm)          7.89 ± 3.23         9.23 ± 3.36           6.75 ± 2.49             0.001
  tRCE (%)                78.34 ± 45.34       92.153 ± 101.34       40.592 ± 11.019         0.017
  aRCE (%)                124.45 ± 61.11      181.46 ± 97.80        92.63 ± 45.48           \< 0.001
  pRCE (%)                254.21 ± 198.22     321.90 ± 231.03       201.32 ± 124.66         0.020
  dRCE (%)                377.15 ± 223.21     466.18 ± 260.08       271.91 ± 209.66         0.002
  MaRIA                                                                                     
  tRCE                    20.37 ± 3.42        26.18 ± 5.02          6.44 ± 1.03             \< 0.001
  aRCE                    18.88 ± 4.11        28.40 ± 4.84          6.43 ± 2.74             \< 0.001
  pRCE                    26.32 ± 2.89        35.09 ± 4.64          6.94 ± 2.58             \< 0.001
  dRCE                    19.26 ± 3.21        36.81 ± 5.11          7.25 ± 2.32             0.001
  CDEIS                   8.15 ± 4.03         10.57 ± 3.02          3.46 ± 1.23             0.001

IFX: Infliximab; ADA: Adalimumab; CRP: C-reactive protein; ADC: Apparent diffusion coefficient; tRCE: Total relative contrast enhancement; aRCE: Arterial relative contrast enhancement; pRCE: Portal phase relative contrast enhancement; dRCE: Delay phase relative contrast enhancement; MaRIA: Magnetic resonance index of activity; CDEIS: Crohn's disease endoscopic index of severity.

MRI agreement
-------------

An inter-observer agreement evaluation between the two radiologists was performed using kappa statistics, which showed a high correlation (0.936) when considering all parameters. Therefore, the average results of the two radiologists were used for evaluation.

Before treatment
----------------

Table [1](#T1){ref-type="table"} presents the MRI findings before treatments. Higher proportions of patients in the active group showed edema, mucosal ulcer, enhancement pattern, morphological changes, and perienteric exudation than in the inactive group (all *P \<* 0.05).

On MRI and compared with the inactive group, the active group showed lower ADC (*P =* 0.001) and higher thickness, tRCE, aRCE, pRCE, dRCE, and MaRIA (all *P \<* 0.05). At endoscopy, the active group showed higher CDEIS scores than the inactive group (*P =* 0.001) (Table [1](#T1){ref-type="table"}).

MRI quantitative parameters (ADC value, bowel thickness, tRCE, aRCE, pRCE, dRCE, and MaRIA scores) were significantly correlated with CDEIS. The highest correlation was found between MaRIA and CDEIS with coefficients of *r =* 0.772 for tRCE, *r =* 0.754 for aRCE, *r =* 0.738 for pRCE, and *r =* 0.712 for dRCE, followed by tRCE, aRCE, pRCE, dRCE, bowel thickness, and ADC value (*r =* 0.661, 0.634, 0.518, 0.507, 0.356, and -0.276, respectively) (Table [1](#T1){ref-type="table"}).

In the active CD group, CDEIS was significantly correlated with MaRIAs, tRCE, aRCE, pRCE, dRCE, bowel thickness, and ADC, with coefficients of *r =* 0.789, 0.767, 0.745, 0.718, 0.726, 0.548, 0.54, 0.459, 0.311, and -0.207, respectively (Table [2](#T2){ref-type="table"}). On the other hand, in the inactive CD group, MaRIA (for tRCE), and tRCE were positively correlated with CDEIS (*r =* 0.746 and 0.718, respectively) (Table [2](#T2){ref-type="table"}, and Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![Magnetic resonance imaging of a typical case of active Crohn's disease before treatment. Female, 32 years of age, active Crohn's disease. A: T2WI showed intestinal wall thickening and submucosal edema in the distal ileum; B: Fast imaging employing steady-state acquisition showed intestinal wall thickening and submucosal edema in the distal ileum; C: Diffusion weight imaging showed marked high intensity; D and E: Dynamic enhancement showed obvious layer stratified enhancement.](WJG-24-2279-g001){#F1}

###### 

Correlations between magnetic resonance indicators and Crohn's disease endoscopic index of severity before treatment in the two groups

              **All *n* = 104**   **Active group *n* = 61**   **Inactive group *n* = 43**                            
  ----------- ------------------- --------------------------- ----------------------------- ---------- ------------- ----------
  ADC         -0.276              0.012                       -0.207                        0.016      -0.202        0.356
  Thickness   0.356               0.001                       0.311                         0.002      0.952         0.013
  tRCE        0.661               \< 0.001                    0.726                         \< 0.001   0.718         \< 0.001
  aRCE        0.634               \< 0.001                    0.548                         \< 0.001   0.238         0.274
  pRCE        0.519               \< 0.001                    0.540                         \< 0.001   0.921         0.022
  dRCE        0.507               \< 0.001                    0.459                         \< 0.001   0.022         0.920
  MaRIA                                                                                                              
  tRCE        0.772               \< 0.001                    0.789                         \< 0.001   0.746         \< 0.001
  aRCE        0.754               \< 0.001                    0.767                         \< 0.001   0.334         0.288
  pRCE        0.738               \< 0.001                    0.745                         \< 0.001   0.230         0.471
  dRCE        0.712               \< 0.001                    0.718                         \< 0.001   0.280         0.378
  CDEIS       8.15 ± 4.03                                     10.57 ± 3.02                             3.46 ± 1.23   

ADC: Apparent diffusion coefficient; tRCE: Total relative contrast enhancement; aRCE: Arterial relative contrast enhancement; pRCE: Portal phase relative contrast enhancement; dRCE: Delay phase relative contrast enhancement; MaRIA: Magnetic resonance index of activity; CDEIS: Crohn's disease endoscopic index of severity.

![Magnetic resonance imaging of a typical case of active Crohn's disease after treatment (same patient as in Figure [1](#F1){ref-type="fig"}). She remained in the active Crohn's disease group after treatment. A: T2WI showed intestinal wall thickened and submucosal edema decrease in the distal ileum; B: Fast imaging employing steady-state acquisition showed intestinal wall thickened and submucosal edema decrease in the distal ileum; C: Diffusion weight imaging showed less high intensity; D and E: Dynamic enhancement showed layer stratified enhancement.](WJG-24-2279-g002){#F2}

After treatment
---------------

All 61 patients in the active group underwent MRI and endoscopy examinations after medical treatment. The correlation coefficients between CDEIS and MaRIAs were *r =* 0.771 for MaRIA of aRCE, *r =* 0.755 for MaRIA of dRCE, *r =* 0.740 for MaRIA of pRCE, and *r =* 0.736 for MaRIA of tRCE, which were all higher than that between CDEIS and single MRI parameters. Among single MRI indicators, the highest correlation was found for aRCE. The same correlation order was found between ∆MaRIAs and ∆CDEIS as that between MaRIAs and CDEIS. For single ∆MRI indicators, the correlation was in the order of ∆aRCE \> ∆ADC \> ∆pRCE \> ∆dRCE \> ∆tRCE, with *r =* 0.593, -0.545, 0.529, 0.512, and 0.467, respectively (Table [3](#T3){ref-type="table"}). No correlation was observed between CDEIS and bowel thickness (Table [3](#T3){ref-type="table"}).

###### 

Correlations between magnetic resonance imaging indicators and Crohn's disease endoscopic index of severity in the 61 active Crohn's disease patients after treatment

              **CDEIS**              **ΔCDEIS**            
  ----------- ----------- ---------- ------------ -------- ----------
  ADC         -0.467      \< 0.001   ΔADC         -0.545   0.001
  Thickness   0.242       0.201      Δthickness   0.407    0.148
  tRCE        0.548       0.002      ΔtRCE        0.467    0.018
  aRCE        0.619       \< 0.001   ΔaRCE        0.593    0.002
  pRCE        0.493       0.008      ΔpRCE        0.529    0.004
  dRCE        0.490       0.015      ΔdRCE        0.512    0.003
  MaRIA                              ΔMaRIA                
  tRCE        0.736       \< 0.001   tRCE         0.724    \< 0.001
  aRCE        0.771       \< 0.001   aRCE         0.781    \< 0.001
  pRCE        0.740       \< 0.001   pRCE         0.724    \< 0.001
  dRCE        0.755       \< 0.001   dRCE         0.760    \< 0.001

ADC: Apparent diffusion coefficient; tRCE: Total relative contrast enhancement; aRCE: Arterial relative contrast enhancement; pRCE: Portal phase relative contrast enhancement; dRCE: Delay phase relative contrast enhancement; MaRIA: Magnetic resonance index of activity; CDEIS: Crohn's disease endoscopic index of severity.

After treatment, 17 of the 61 patients remained with active CD. Table [4](#T4){ref-type="table"} presents the characteristics of these patients. Gender, age, disease duration, disease location, and CRP levels were similar between the two groups. The inactive group showed better clinical and MRI performances than the active group after treatments (all *P \<* 0.05). In those 17 patients, no statistical correlation was found between endoscopy score and MRI indicators. The remaining 44 patients remitted into inactive CD. The correlations between CDEIS and MRI parameters in these 44 cases were in the order of MaRIA for aRCE \> MaRIA for tRCE \> MaRIA for pRCE \> MaRIA for dRCE \> aRCE \> ADC value \> tRCE \> pRCE \> dRCE, with *r =* 0,712, 0.705, 0.685, 0.634, 0.697, -0.516, 0.420, 0.350, and 0.341, respectively (Table [5](#T5){ref-type="table"}).

###### 

Subgroups in the active Crohn's disease patients according to disease activity after treatments

                       **Remained active (*n* = 17)**   **Improved to inactive (*n* = 44)**   ***P* value**                     
  -------------------- -------------------------------- ------------------------------------- ---------------- ---------------- ----------
  Gender (M/F)         10/7                                                                   26/18                             0.332
  Age                  30.4 ± 5.5                                                             26.7 ± 10.1                       0.563
  Disease duration     1-5                                                                    1-5                               
  Disease location                                                                                                              0.916
  Sigmoid/left colon   1                                                                      1                                 
  Transverse colon     3                                                                      4                                 
  Right colon          4                                                                      6                                 
  Ileum                14                                                                     28                                
  Treatment regimen                                                                                                             0.292
  Glucocorticoids      8                                                                      15                                
  Infliximab           6                                                                      12                                
  Adalimumab           3                                                                      17                                
  CRP                  28.01 ± 5.22                                                           20.91 ± 5.45                      0.054
  CDEIS                12.23 ± 5.12                     10.47 ± 3.43                          10.12 ± 2.11     3.11 ± 0.21      0.001
  CRP                  28.01 ± 5.215                    15.12 ± 4.32                          20.91 ± 5.45     5.84 ± 0.743     0.002
  ADC                  1.52 ± 0.12                      1.44 ± 0.34                           1.59 ± 0.17      1.73 ± 0.2       0.001
  Thickness            9.12 ± 1.21                      7.66 ± 1.41                           8.2 ± 2.22       5.42 ± 1.32      0.012
  tRCE                 89.14 ± 13.33                    69.49 ± 12.11                         82.11 ± 12.47    45.32 ± 4.53     0.021
  aRCE                 179.03 ± 20.66                   166.16 ± 22.44                        181.14 ± 34.1    89.76 ± 12.71    0.001
  pRCE                 330.02 ± 67.12                   285.27 ± 57.71                        301.32 ± 54.12   199.23 ± 23.2    0.001
  dRCE                 453.29 ± 54.05                   385.5 ± 45.32                         440.18 ± 33.09   257.22 ± 44.13   0.001
  MaRIA                                                                                                                         
  tREC                 35.17 ± 5.66                     30.12 ± 3.12                          26.56 ± 2.90     6.23 ± 1.11      \< 0.001
  aRCE                 28.22 ± 6.76                     19.12 ± 4.09                          29.47 ± 5.22     6.48 ± 1.38      \< 0.001
  pRCE                 37.79 ± 5.59                     29.21 ± 4.21                          36.28 ± 4.72     7.11 ± 1.74      \< 0.001
  dRCE                 36.09 ± 8.12                     25.2 ± 5.77                           27.08 ± 5.79     7.22 ± 1.59      \< 0.001
  ESR                  24.186 ± 3.210                   18.28 ± 3.38                          21.49 ± 3.33     3.184 ± 0.568    \< 0.001

CRP: C-reactive protein; ADC: Apparent diffusion coefficient; tRCE: Total relative contrast enhancement; aRCE: Arterial relative contrast enhancement; pRCE: Portal phase relative contrast enhancement; dRCE: Delay phase relative contrast enhancement; MaRIA: Magnetic resonance index of activity; CDEIS: Crohn's disease endoscopic index of severity; ESR: Erythrocyte sedimentation rate.

###### 

Correlations between magnetic resonance indicators and Crohn's disease endoscopic index of severity in the active group according to disease activity after treatment

              **Remained active *n* = 17**   **Improved to inactive *n* = 44**            
  ----------- ------------------------------ ----------------------------------- -------- ----------
  ADC         -0.219                         0.518                               -0.516   0.002
  Thickness   0.105                          0.758                               0.170    0.568
  tRCE        0.356                          0.203                               0.420    0.005
  aRCE        0.376                          0.255                               0.697    0.002
  pRCE        0.305                          0.113                               0.350    0.010
  dRCE        0.381                          0.134                               0.341    0.015
  MaRIA                                                                                   
  tRCE        0.268                          0.400                               0.705    \< 0.001
  aRCE        0.268                          0.399                               0.712    \< 0.001
  pRCE        0.306                          0.334                               0.685    \< 0.001
  dRCE        0.309                          0.329                               0.634    \< 0.001

ADC: Apparent diffusion coefficient; tRCE: Total relative contrast enhancement; aRCE: Arterial relative contrast enhancement; pRCE: Portal phase relative contrast enhancement; dRCE: Delay phase relative contrast enhancement; MaRIA: Magnetic resonance index of activity.

Among MRI qualitative indicators, statistical analysis could not be done for mucosal ulcer because of its low frequency (16/61). Edema in the submucosa and perienteric exudation were decreased (61/61 and 18/18) after treatment. In addition, the enhancement pattern of the bowel wall in inactive CD patients changed to non-stratified enhancement (44/61), whereas it remained stratified enhancement in active CD patients (17/61) (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

![Magnetic resonance imaging of a typical case of active Crohn's disease before treatment. Male, 25 years of age, active Crohn's disease. A: Fast imaging employing steady-state acquisition showed intestinal wall thickening and submucosal edema in the ascending colon; B and C: T2WI showed intestinal wall thickening and submucosal edema in the ascending colon; D and E: Dynamic enhancement showed obvious enhancement; F: Diffusion weight imaging showed marked high intensity.](WJG-24-2279-g003){#F3}

![Magnetic resonance imaging of a typical case of active Crohn's disease after treatment (same patient as in Figure [3](#F3){ref-type="fig"}). The patient was in remission (inactive Crohn's disease) after treatment. A: Fast imaging employing steady-state acquisition showed decreased intestinal wall thickening and no submucosal edema; B and C: T2WI showed decreased intestinal wall thickening and no submucosal edema; D: Diffusion weight imaging showed less high intensity; E: Enhancement showed less enhancement.](WJG-24-2279-g004){#F4}

DISCUSSION
==========

MRI is fairly reproducible but shows only a moderate agreement with CDEIS\[[@B6],[@B12],[@B13]\]. Furthermore, the concordance of the two examinations during follow-up or before/after treatment remains uncertain. Therefore, this study aimed to examine the correlation and concordance among multiple MRI findings and CDEIS changes before and after CD treatment. The results strongly suggest that MRI artery phase-enhanced indexes were the most sensitive indicators, especially arterial MaRIA, for CD follow-up and dynamic assessment of the therapeutic effects. CD treatment assessment was not completely concordant between CDEIS and MRI.

The clinical course of CD usually presents an acute-remission-recur cycle. Therefore, regular monitoring and follow-up are needed. The assessment methods for the diagnosis and follow-up include clinical manifestations, endoscopy, histopathology, computed tomography (CT), and MRI\[[@B18]\]. In clinical practice, there is often a low correlation between clinical symptoms and bowel inflammatory activity. Clinical symptoms may be unrelated to endoscopy and imaging findings\[[@B19],[@B20]\]. Endoscopy and histopathology exams are the first choice for the diagnosis of CD\[[@B1],[@B18]\]. Nevertheless, these approaches are invasive and ill-suited for regular monitoring and follow-up. Therefore, MRI is probably one of the most appropriate methods for the long-term evaluation and monitoring of CD.

An early study on the efficacy of CD treatment was reported using MRI enhanced index and bowel thickness\[[@B21]\]. Other MRI evaluations, such as mucosal ulcer and ADC value, were used in recent studies\[[@B22]\]. Some studies\[[@B23]-[@B27]\] focused on the accuracy of MRI indicators for the evaluation of CD and the response to medical therapy. One study reported that changes in CD clinical activity were significantly correlated with changes in MRI activity score\[[@B28]\]. Bowel wall thickening, mesenteric lymphadenopathy, and fat wrapping with vascular proliferation were the MRI parameters that changed significantly after induction and maintenance treatment in responders\[[@B28]\]. The changes in MRI activity score were mostly pronounced during the first 3 months of treatment compared with long-term treatments (weeks 52-54)\[[@B28]\]. In the present study, both MRI scores (MaRIA) and single MRI indicators (ADC, tRCE, aRCE, pRCE, dRCE, and bowel thickness) were evaluated. After treatment, MaRIA scores, ADC, tRCE, aRCE, pRCE, dRCE, ∆ADC, ∆tRCE, ∆aRCE, ∆pRCE, and ∆dRCE remained correlated with CDEIS, but bowel thickness was not, possibly because CD is a chronic and recurrent disease. Both edema and chronic fibrosis can be found in thickened bowel segment. After effective medical therapy, inflammation may be improved and edema may have regressed, but fibrous adipose tissue hyperplasia may be present or become more serious. This may weaken the correlation between bowel thickness and CDEIS. Secondly, compared with other studies, the evaluation timing after treatment was different. Therefore, the decision when to make the MRI evaluation is still an issue. Various MRI assessment timings may produce different results in treatment effect. Thirdly, our sample size was limited. Nevertheless, a recent study supports the use of MaRIA for the evaluation of CD\[[@B29]\].

In the present study, higher correlations were found for MaRIA scores than that for single MRI indicators. Among them, the MaRIA score of aRCE showed the best correlation after treatment. Among single MRI indicators, the best correlation was found between aRCE and CDEIS. Possible reasons that MRI artery phase enhanced indexes were the most sensitive for efficacy assessment after CD treatment may be decreased blood supply to mucosal ulcer and improved inflammation.

Nevertheless, each correlation coefficient of enhanced indexes was decreased compared with those before treatment in 61 patients with CD. In general, MRI findings, as a treatment evaluation method, were not completely matched with CDEIS, especially after 24-26 wk of effective treatment. Grouped by treatment effect, good correlation between MRI and CDEIS results was found in active CD patients who experienced remission but not among those who remained with active CD after treatment. This finding may also reflect that time has an impact on the changes between MRI and CDEIS.

DWI has recently been shown to be an appropriate tool for the follow-up of CD\[[@B30],[@B31]\]. In the present study, the correlation between ADC values and CDEIS after treatment was increased compared with that before treatment, especially ∆ADC. Though ADC value was proved to be a reliable independent indicator for the evaluation of CD and with a similar value to that of enhancement indicators in previous studies\[[@B9],[@B22]\], the present study showed that it was more valuable and reliable to follow-up the change of ADC values for dynamic monitoring. It had a good value reflecting CD prognosis during periods rather than at specific time point of the disease.

Among qualitative indicators, because of strict requirement for bowel distension, no advantage was shown for MRI detecting mucosal ulcer compared with endoscopy. Other MRI indicators, such as edema, exudation, and enhancement pattern, were sensitive and matched the CDEIS changes before and after treatment. Because these are subjective indicators and may vary among observers, they seem to be less accurate and dependable indicators compared with RCE and ADC values. Nevertheless, a study showed that endoscopy and MRI were concordant, even without bowel preparation\[[@B32]\]. Additional studies are warranted on this point.

The present study is not without limitations. The sample size was small and from a single center. In addition, the retrospective nature of the study prevented the study of parameters that were not routinely collected. Thirdly, all treated patients were grouped together, but different treatments might have different impact on MRI findings. Finally, MRI T2W1 and T1W1 dynamic enhancement sequences can show intestinal fistula but, in the present study, the frequency of fistula was low. Therefore, reliable statistical analyses could not be performed. Additional studies are necessary to improve upon these results.

In conclusion, MRI indicators were correlated with CDEIS, but such correlation was decreased in patients with active CD that became inactive after treatment. CD treatment assessment was not completely concordant between CDEIS and MRI. MRI artery phase enhanced indexes seemed to be the most sensitive indicators, especially MaRIA score of aRCE. MaRIA scores were better than single MRI indicators for CD follow-up and dynamic assessment of therapeutic effects.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Crohn's disease (CD) is an inflammatory bowel disease that may involve the entire gastrointestinal tract. CD easily recurs, and accurate and comprehensive evaluation and follow-up are essential to design an individualized treatment program. Crohn's Disease Endoscopic Index of Severity (CDEIS) is generally used to assess CD activity. However, it is currently uncertain whether MRI abnormalities are concordant with changes in CDEIS. In addition, whether MRI is only a supplementary/accessory assessment method to endoscopy or could substitute endoscopy during follow-up remains unclear.

Research motivation
-------------------

The clinical symptoms of CD may be unrelated to endoscopy and imaging findings. Endoscopy and histopathology are the first methods of choice for the diagnosis of CD. Nevertheless, these approaches are invasive and ill-suited for regular monitoring and follow-up. Therefore, MRI is probably one of the most appropriate methods for long-term evaluation and monitoring of CD.

Research objectives
-------------------

We hypothesized that CDEIS changes correlated with MaRIA scores as well as individual MRI parameters before and after CD treatment. The present study aimed to help us to understand the pathological changes of CD and provide non-invasive modalities for examining therapeutic effects.

Research methods
----------------

One hundred and four patients with CD were analyzed retrospectively. Among them, 61 and 43 patients were considered to have active CD (CDEIS \> 6) and inactive CD (CDEIS ≤ 6), respectively. MaRIA scores as well as individual MRI parameters, including total relative contrast enhancement (tRCE), arterial RCE (aRCE), portal RCE (pRCE), delay phase RCE (dRCE), and apparent diffusion coefficient (ADC), were evaluated. Correlation and concordance between multiple MRI findings and CDEIS were examined.

Research results
----------------

In the present study, we found that CDEIS had correlations with MaRIAs at baseline in all patients, including tRCE, aRCE, pRCE, dRCE (all MaRIAs, *P \<* 0.001), followed by single MRI indexes. Among the 61 active CD patients, 44 cases were remitted to inactive CD after treatment. In the 44 patients who achieved remission, correlations between CDEIS and all MaRIAs remained after treatment. However, the values of the correlation coefficient (r) were decreased. The most significant correlations were found between MaRIAs for aRCE and CDEIS.

Research conclusions
--------------------

MRI indicators had correlations with CDEIS in patients with active CD before treatment. However the correlations were decreased in patients with active CD that became inactive after treatment. The assessment was not completely concordant between CDEIS and MRI in patient with CD before and after treatment. The MaRIA score of aRCE seemed to be an important indicator. For dynamic assessment of therapeutic effects, MaRIA scores were better than single MRI indicators.

Research perspectives
---------------------

Endoscopic results were not completely consistent with MR data among CD patients. The most sensitive indicators in evaluating efficacy by MR were relevant indicators during the MR enhanced arterial phase. The most appropriate timing for performing MR evaluation and monitoring disease conditions after treatment of CD should be explored in the future.
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